Examkin

Soru

Zorluk: Çok zorBipolar and Related Disorders

A 41-year-old man is brought to the clinic by his wife due to severe anhedonia, feelings of worthlessness, and hypersomnia lasting for the past six weeks. He has a past medical history of obesity (BMI 36 kg/m²), poorly controlled type 2 diabetes mellitus, and essential hypertension. His current daily medications are metformin, valsartan, and indapamide. His wife reports that three years ago, he experienced a distinct three-week period where he slept only two hours per night, spoke incessantly, and exhibited grandiosity, claiming he was a covert operative for a secret intelligence agency. That episode resolved without psychiatric intervention, and he has taken no psychotropic medications since. Mental status examination reveals psychomotor slowing, poor eye contact, and a severely depressed mood, but no current delusions or hallucinations. Which of the following is the most appropriate next step in pharmacologic management?

  1. Initiate cariprazine therapyCevap
  2. B
    Initiate fluoxetine therapy
  3. C
    Initiate lithium carbonate therapy
  4. D
    Initiate paroxetine and phenelzine therapy
  5. E
    Initiate risperidone therapy for schizophreniform disorder

Cevap

Initiate cariprazine therapy
The correct answer is to initiate cariprazine therapy. This patient presents with an acute depressive episode but has a clear history of a manic episode with psychotic features (grandiosity, decreased need for sleep, rapid speech), making the diagnosis Bipolar I disorder. The treatment of acute bipolar depression requires mood stabilizers or specific second-generation antipsychotics. While lithium is a classic first-line agent, this patient is taking valsartan (an angiotensin II receptor blocker) and indapamide (a thiazide-like diuretic). Both classes of drugs dramatically reduce the renal clearance of lithium, creating a severe risk for fatal lithium toxicity; therefore, lithium should be strictly avoided or would require highly specialized dosage adjustments. Furthermore, the patient's comorbid obesity and type 2 diabetes mellitus make metabolically adverse atypical antipsychotics (such as olanzapine or quetiapine) less favorable. Cariprazine and lurasidone are FDA-approved for bipolar depression, have highly favorable metabolic profiles, and do not have dangerous pharmacokinetic interactions with the patient's antihypertensive regimen.

Adım Adım Çözüm

1
Identify the primary psychiatric diagnosis.
The patient has Bipolar I disorder, currently in a severe depressive episode, based on his current symptoms and a past history of a manic episode with psychotic features.
Accurate diagnosis is required to avoid prescribing antidepressant monotherapy, which can trigger a manic switch.
2
Evaluate the patient's medical comorbidities.
The patient has severe obesity and type 2 diabetes mellitus.
These comorbidities contraindicate the use of metabolically adverse atypical antipsychotics (like olanzapine or quetiapine) for bipolar depression.
3
Evaluate for potential drug-drug interactions with current medications.
The patient takes valsartan (an ARB) and indapamide (a thiazide-like diuretic).
Both ARBs and thiazide diuretics significantly decrease renal clearance of lithium, making lithium carbonate a highly dangerous choice due to the risk of fatal toxicity.
4
Select the optimal pharmacotherapy.
Cariprazine is the safest and most effective option.
Cariprazine is FDA-approved for bipolar depression, does not interact dangerously with his antihypertensives, and is metabolically neutral.

Anahtar Kavram

Management of acute bipolar depression with medical comorbidities and preventing adverse drug interactions
Bu soruyu puanla

Konular

Bipolar and Related Disorders

Bu konudan daha fazla soru